Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGER1 | P34995 | 6/20 | 0.39 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.38 |
| ▸ | P2RX4 | Q99571 | 1/20 | 0.37 |
| ▸ | CSF1R | P07333 | 1/20 | 0.36 |
| ▸ | MET | P08581 | 1/20 | 0.36 |
| ▸ | PPIA | P62937 | 1/20 | 0.36 |
| ▸ | MRGPRX4 | Q96LA9 | 1/20 | 0.35 |
| ▸ | LMNA | P02545 | 1/20 | 0.35 |
| ▸ | MCHR1 | Q99705 | 2/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6936342 | 0.88 | GABRA1 (0.38) | PTGER1P2RX4CSF1RMETPPIA | |
| SCHEMBL6942080 | 0.80 | RORC (0.40) | PTGER1CYP19A1P2RX4METPPIA | |
| SCHEMBL7076172 | 0.76 | MEN1 (0.45) | PTGER1CYP19A1P2RX4PPIAMRGPRX4 | |
| SCHEMBL7561698 | 0.75 | RORC (0.41) | PTGER1CYP19A1P2RX4CSF1RPPIA | |
| SCHEMBL7127088 | 0.75 | MRGPRX4 (0.49) | CYP19A1P2RX4METPPIAMRGPRX4 | |
| SCHEMBL5099764 | 0.74 | MET (0.46) | CYP19A1P2RX4METPPIAMRGPRX4 | |
| SCHEMBL7561577 | 0.74 | CYP19A1 (0.42) | PTGER1CYP19A1P2RX4PPIAMRGPRX4 | |
| SCHEMBL7121876 | 0.73 | ALDH1A1 (0.49) | CYP19A1P2RX4LMNA | |
| SCHEMBL7562213 | 0.72 | MAPT (0.35) | CSF1RLMNA | |
| SCHEMBL7122686 | 0.71 | P2RX4 (0.44) | PTGER1CYP19A1P2RX4METPPIA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20020183519-A1 | Antithrombotic carboxylic acid amides | BOEHRINGER INGELHEIM PHARMA KG (DE) | 2002-12-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020183519-A1 | Antithrombotic carboxylic acid amides | SERPINC1, TFPI, F2 | PTGER1 299/4885CYP19A1 1031/4885P2RX4 1710/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.